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ABSTRACT The effects of a soluble cocoa fiber (SCF) were studied in Zucker fatty rats. Two groups of Zucker fatty rats
were fed the following diets: standard diet and 5% SCF-enriched diet. A group of Zucker lean rats fed the standard diet was
used for results comparison with obese Zucker animals. Solid and liquid intakes, body weight, plasma glucose, lipid profile,
and systolic (SBP) and diastolic (DBP) blood pressure were recorded weekly. At the end of the experimental period insulin
was determined, and fat apparent digestibility (FAD) and insulin resistance were calculated. The Zucker fatty rats fed 5%
SCF-enriched diet showed less weight gain and food intake than those fed the standard diet. The group fed the fiber-enriched
diet showed lower values of the total cholesterol=high-density lipoprotein cholesterol ratio and triglyceride levels than the
standard group. FAD was also lower in the fiber group. Both SBP and DBP were decreased. In addition, SCF reduced plasma
glucose and insulin, and as a consequence the insulin resistance was also decreased. Our data demonstrate that SCF resulted in
an improvement of the studied risk factors associated with cardiometabolic disorders.
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INTRODUCTION
The metabolic syndrome is emerging as one of themost important public health problems in the world. This
metabolic disorder can be defined as a cluster of health prob-
lems, caused by genetic and environmental factors, whose
common fundamental pathogenic component is resistance to
insulin.1–3 It has been reported that dietary fiber appears to be
particularly beneficial in the control of the most of the met-
abolic disturbances clustered in the metabolic syndrome.4,5
Dietary fiber is the name given to groups of components
present in foods of vegetable origin (cereals, fruit, vegetables,
and pulses) that are not broken down by human digestive
enzymes.6 Dietary fiber can be subdivided or classified into
insoluble and soluble fiber. The principal beneficial effects
of a fiber-rich diet in patients with metabolic syndrome are
prevention of obesity, improved glucose levels, and control
of the profile of blood lipids.7 It has also been suggested that
dietary fiber may favor the control of arterial blood pres-
sure.8 There is therefore a growing interest in discovering
new sources of natural fiber that may be used as functional
ingredients to obtain foods with properties that are beneficial
to health.
Cocoa (Theobroma cacao L.) is widely used in the
chocolate industry. Much attention has been paid in recent
years to cocoa and cocoa products because of their potential
benefits on health. Cocoa husk is a waste product from the
chocolate industry. This by-product is frequently used as
secondary source of theobromine and caffeine but could also
offer a valuable and cheap source of dietary fiber. A product
rich in soluble cocoa fiber (SCF) was obtained by a patented
enzymatic process from cocoa husk.9 In a previous work
the beneficial effect of 10% SCF in hypercholesterolemic
Sprague-Dawley rats was demonstrated; the results showed
an improvement in lipid profile and an important decrease of
body weight.10
Zucker fatty rats are considered the best-known and
most widely used experimental model of genetic obesity.
These animals present also dyslipidemia, mild glucose in-
tolerance, and hyperinsulinemia, alterations similar to those
that appear in the human metabolic syndrome. These ani-
mals can, in fact, be also considered a model of resistance
to insulin, whereas Zucker lean rats are insulin sensitive
and normoinsulinemic and have a normal tolerance of glu-
cose.11–14
The aim of the present study was to evaluate in an ex-
perimental animal model the effect of SCF on the main
cardiometabolic risk factors that characterize the human
metabolic syndrome (obesity, impaired glucose tolerance,
dyslipidemia, and hypertension). In the present study, 5%
SCF-enriched diet was fed to Zucker fatty rats. Therefore we
evaluate in these animals the effect of a lower dose of SCF
than the one used in the previous study.10 A group of Zucker
lean rats was used for results comparison with nonobese
Zucker animals.
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MATERIALS AND METHODS
General protocol
Twenty female 8-week-old Zucker fatty rats weighing
260–275 g and 10 female 8-week-old Zucker lean rats
weighing 150–175 g, purchased from Charles River La-
boratories (Barcelona, Spain), were used in this study. The
Zucker fatty rats were randomly divided into two groups of
10 animals that were fed the following diets until week 15 of
life: standard diet or 5% SCF-enriched diet. The lean Zucker
rats were only used to provide normal values in the Zucker
strain, and they were in turn fed the standard diet until week
15 of life. During the experimental period the animals were
maintained at a temperature of 238C, with 12-hour light=dark
cycles, and were fed ad libitum with free access to water.
Food intake, water intake, and body weight gain were
recorded on a weekly basis in the different groups of rats.
Plasma total cholesterol, plasma cholesterol transported by
high-density lipoproteins (HDL cholesterol), triglycerides,
and glucose were also measured on a weekly basis. Because
the usual biochemical procedures to determine the choles-
terol transported in plasma by low-density lipoproteins in
Zucker rats are not reliable, we calculated the ratio total
cholesterol=HDL cholesterol. This ratio is known in clinical
practice as the ‘‘atherogenic index.’’ In order to carry out all
the determinations mentioned above, blood extractions from
the jugular vein were performed weekly in the rats after an
overnight fasting.
Systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP) were measured weekly in the rats during the
experimental period, by the tail cuff method.15 The original
technique for measuring arterial blood pressure using the tail
cuff method provides only SBP values; however, the equip-
ment used in this study (LE 5001 pressure meter, Letica
Scientific Instruments, Barcelona), has a high-sensitivity
pulse transducer coupled with an accurate microprocessor
program, thus allowing us to distinguish between SBP and
DBP. Before the measurements, the rats were kept at 388C
for 10–15 minutes to make the pulsations of the tail artery
detectable. Arterial blood pressure measurements were per-
formed at the same time of day (between 9 a.m. and 1 p.m.)
in order to avoid the influence of the circadian cycle, and the
values of SBP and DBP were obtained by estimating the
average reading of five measurements.
During the last week of treatment the animals were placed
in metabolic cages. Feces were collected, and the weight
was recorded. They were pooled, sealed in Falcon tubes
(BD, Franklin Lakes, NJ, USA), and frozen until analysis.
The samples were dried to constant weight, and fat content
was determined by the Soxhlet method using petroleum
ether.16 The fat apparent digestibility (FAD) was calculated
for each animal as 100(fat intake – fat output)=fat intake.
Fat intake was in turn estimated taking into account the com-
position of diets, and the fat content in feces was considered
the fat output.
At the end of the experimental period all the rats were
sacrificed by decapitation after an overnight fasting. Blood
was obtained from the sacrificed rats to carry out the same
biochemical determinations that we had performed weekly,
and the corresponding values of atherogenic index were also
calculated. In addition, plasma insulin was determined.
Moreover, fasting plasma concentrations of both glucose
and insulin were used to calculate indices of insulin resis-
tance (homeostasis model assessment-insulin resistance
[HOMA-IR] and insulin secretion [HOMA-b]) with the follo-
wing formulae17: HOMA-IR¼ fasting insulin (in mU=mL)
fasting glucose (in mM)=22.5; HOMA-b¼ 20fasting insu-
lin (in mU=mL)=[fasting glucose (in mM) – 3.5].
In this study, all the experiments were performed as au-
thorized for scientific research (European Directive 86=609=
CEE and Royal Decree 223=1988 of the Spanish Ministry of
Agriculture, Fisheries and Food).
Diets
Two synthetic diets were used in this study (Table 1).
They were prepared by Harlan Interfauna Ibe´rica, Barce-
lona. The first one (AIN-93M purified Rodent Diet) was a
standard diet that provides the nutrients required by adult
rats according to the National Research Council guide-
lines.18 The other diet contained 5% SCF (from SCF product
provided by Natraceutical Group, Valencia, Spain). The two
diets were prepared and formulated to provide the same
amount of protein (14%), fat (4%), and carbohydrates (72%)
and therefore the same energy value.
Analytical procedures
Blood samples were collected into tubes containing lith-
ium heparin as anticoagulant. These samples were centri-
fuged at 2,500 g for 20 minutes at 48C to obtain the plasma,
which was divided into aliquots and kept frozen at 808C
until analysis.
Table 1. Composition of the Diets
g=100 g dry weight
Standard diet 5% SCF
Protein 14 14
Casein 14 11.8
Fat 4 4
Soybean oil 4 3.36
Carbohydrate 72 72
Sucrose 10 8.70
Dextrin 15.5 13.49
Cornstarch 46.56 40.53
Powdered cellulose 5 5
SCF producta 0 12.15
tert-Butylhydroquinone 0.0008 0.0008
AIN 93 mineral mixture 3.5 3.5
AIN 93 vitamin mixture 1 1
l-Cystine 0.18 0.18
Choline bitartrate 0.25 0.25
Energy (kJ=100 g) 1,589 1,589
The carbohydrate substitution in the experimental diets was formulated at
the expense of sucrose, dextrin, and cornstarch proportionally.
aSCF product contains protein (17.92%) and fat (5.26%); the exact amount
of soluble fiber is 41.16%.
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The lipid profile (total cholesterol, HDL cholesterol, and
triglycerides) and plasma glucose were assayed by using
enzymatic and colorimetric methods with commercial kits
(Roche Diagnostics S.L., Barcelona). The different concen-
trations of these variables were determined spectrophoto-
metrically with a Hitachi (Roche Farma, Madrid, Spain)
model 911 autoanalyzer (wavelength, 700 nm). The plasma
insulin concentration was spectrophotometrically quantified
by using an ultrasensitive rat insulin enzyme immunoassay
kit (Mercodia AB, Uppsala, Sweden) with a Thermomax
microplatereader(MolecularDevices,Sunnyvale,CA,USA).
The absorbance was measured at 450 nm.
Statistical analysis
The results are expressed as meanSEM values for a
minimum of eight rats and were analyzed by a two-way
analysis of variance, using GraphPad (San Diego, CA, USA)
Prism version 4 software. In addition, to assess the effect of
time within each treatment and to compare the variables that
were only determined at the end of the experimental period,
some data were also analyzed by a one-way analysis of
variance. Differences between the groups were assessed by
the Bonferroni test. Differences between the means were
considered to be significant with P< .05.
RESULTS
Food and liquid intakes and body weight
Food intake throughout the study was significantly higher
in the Zucker fatty rats fed the standard diet than in the
lean rats and the Zucker fatty rats fed the SCF-enriched diet
(Fig. 1A). Water intake was significantly higher in the group
fed the fiber-enriched diet than in the Zucker fatty rats fed
the standard diet and the lean rats (data not shown).
The groups of Zucker fatty rats fed the standard diet and
the SCF-enriched diet progressively gained weight during
the experimental period. However, the weight gain of the
group fed the fiber-enriched diet was significantly lower
than the body weight of the rats fed the standard diet. The
lean group gained also progressively weight during the ex-
perimental period. Nevertheless, as expected, these animals
exhibited a significantly reduced weight compared to the
Zucker fatty rats (Fig. 1B).
Plasma biochemistry
Total cholesterol and HDL cholesterol were significantly
higher in the two groups of Zucker fatty rats than in the
Zucker lean rats. The group of Zucker fatty rats fed the SCF-
enriched diet showed the higher values of total and HDL
cholesterol (Fig. 2A and B). The total cholesterol=HDL
cholesterol ratio, termed the atherogenic index in clinical
practice, of the rats fed the standard diet was significantly
higher than this same ratio in the rats fed the SCF-enriched
diet or the lean rats along the study (Fig. 2C).
Plasma triglycerides were higher in the Zucker fatty rats
than in the Zucker lean rats during all the experimental pe-
riod. The group of Zucker fatty rats fed the standard diet
showed an increase in plasma triglycerides throughout the
study, but the group fed the SCF-enriched diet revealed a
significant decrease in plasma triglycerides compared to this
group (see Fig. 2D).
At the beginning of the experimental period, fasting blood
glucose was markedly higher in the two groups of Zucker
fatty rats than in the Zucker lean rats, but the consumption of
SCF-enriched diet resulted in a significant decrease of
fasting blood glucose along the study (Fig. 2E).
Plasma insulin levels were higher in the Zucker fatty rats
fed the standard diet than in the Zucker lean rats or the Zucker
fatty rats fed the SCF-enriched diet. The consumption of the
SCF-enriched diet resulted in a significant reduction in plasma
insulin level to the extent that no differences were observed
between this group and the lean control group (Fig. 3A). The
Zucker fatty rats fed the standard diet exhibited the highest
values of HOMA-IR and HOMA-b. The SCF-enriched diet
caused a significant decrease in both indices. In fact, HOMA-
b values were similar in the Zucker fatty rats fed the SCF-
enriched diet and in the Zucker lean rats (Fig. 3B and C).
Fat in feces
The fat content in the feces was lower and the FAD was
higher in the Zucker fatty rats compared to the Zucker lean
rats. Fat excretion in the feces increased in the Zucker fatty
rats fed the SCF-enriched diet (Table 2). Significant dif-
ferences were also observed between the FAD of the Zucker
fatty rats fed the 5% SCF-enriched diet and the Zucker fatty
rats fed the standard diet (Fig. 4).
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FIG. 1. (A) Food intake and (B) body weight of different groups
of rats: Zucker fatty rats fed the standard diet (&), Zucker fatty rats
fed 5% SCF-enriched diet (&), and Zucker lean rats fed the standard
diet ( ). Data are mean values SEM for a minimum of eight
rats. Different letters represent statistically significant differences
(P< .05).
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FIG. 2. (A) Plasma total cholesterol, (B) plasma HDL cholesterol, (C) total cholesterol=HDL cholesterol ratio, (D) plasma triglycerides, and (E)
plasma glucose of different groups of rats: Zucker fatty rats fed the standard diet (&), Zucker fatty rats fed 5% SCF-enriched diet (&), and Zucker
lean rats fed the standard diet ( ). Data are mean SEM values for a minimum of eight rats. Different letters represent statistically significant
differences (P< .05).
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FIG. 3. Histograms of (A) plasma insulin, (B) HOMA-IR value, and (C) HOMA-b value of different groups of rats at the end of the experimental
period: Zucker fatty rats fed the standard diet (&), Zucker fatty rats fed 5% SCF-enriched diet (&), and Zucker lean rats fed the standard diet ( ). Data
are mean SEM values for a minimum of eight rats. Different letters represent statistically significant differences (P< .05).
Table 2. Fecal Characteristics of Zucker Rats
Fed Different Diets
Fatty
standard
Fatty
5% SCF
Lean
standard
Feces (g=day)
Wet weight 1.19 0.27a 1.44 0.14ac 2.06 0.06acd
Dry weight 0.41 0.16a 0.71 0.28a 1.94 0.06b
% water in feces 65.55a 50.35ab 5.83c
% fat in feces 0.27a 0.93b 2.6d
Data are mean SEM values for a minimum of eight rats.
abcdDifferent letters represent statistically significant differences (P< .05).
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FIG. 4. Histograms of percentage FAD of different groups of rats in
the last week of the experimental period: Zucker fatty rats fed the
standard diet (&), Zucker fatty rats fed 5% SCF-enriched diet (&),
and Zucker lean rats fed the standard diet ( ). Data are mean SEM
values for a minimum of eight rats. Different letters represent sta-
tistically significant differences (P< .05).
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Blood pressure
SBP and DBP throughout the study were significantly
higher in the Zucker lean rats than in the Zucker fatty rats.
The SBP and DBP values in the Zucker fatty rats fed the
SCF-enriched diet were significantly lower than the corre-
sponding values in the Zucker fatty rats fed the standard diet
(Fig. 5).
DISCUSSION
Zucker fatty rats are the best-known and most widely used
rat model of genetic obesity, and these animals are also
considered as a good experimental model to study different
alterations that characterize the metabolic syndrome.19,20
This disorder is becoming an important public health prob-
lem in western societies, and it is considered as a high-risk
situation for cardiovascular disease. Many epidemiological
studies have documented that nutritional factors, including
fiber intake, may decrease the prevalence of this patho-
logy.21,22 In the present study, Zucker fatty rats were fed
SCF, a soluble fiber that had previously demonstrated
a hypocholesterolemic effect in rats fed cholesterol-rich
diet,10 in order to assess the potentiality of this fiber
in modulating some parameters related to the meta-
bolic syndrome. The present study demonstrates that the
intake of SCF-enriched diet is useful in the prevention
of the main abnormalities clustered in the metabolic syn-
drome, including obesity, dyslipidemia, and glycemic profile.
This study even describes a slight blood pressure-lowering
effect of SCF.
In the present study, the intake of soluble fiber resulted in
a reduction of food body weight. Some researchers also
reported a reduced body weight when high fiber diets were
consumed.5 Pittler and Ernst23 in 2004 carried out a sys-
tematic review to assess the evidence from different studies
on the effectiveness of dietary supplements in reducing body
weight. In this review, data on the following dietary sup-
plements were identified: chitosan, chromium picolinate,
Ephedra sinica, Garcinia cambogia, glucomannan, guar
gum, hydroxylmethylbutyrate, Plantago psyllium, pyruvate,
yerba mate´, and yohimbe. The reviewed studies provide
some encouraging data, but Pittler and Ernst23 concluded that
the evidence for most dietary supplements as aids in reducing
body weight was not convincing. Nevertheless, in the present
study, a marked reduction in body weight gain when SCF is
fed was observed. These findings agree with the previous
reported study using the same product.10
Soluble fiber can exhibit an effect on weight gain through
different mechanisms. The reduced food intake observed in
the rats fed SCF-enriched diet would indicate that a satiating
effect was operating in these animals. According to different
researchers, the reduction in appetite by dietary fiber could
be a consequence of a mechanical intestinal distension and=
or as well delaying carbohydrate digestion and glucose ab-
sorption. The reduced glycemic and insulin responses could
prolong satiety and thus reduce energy consumption.24–27
The low food intake and the glucose and insulin levels ob-
tained in the rats fed SCF-enriched diet would support that
these mechanisms would be also involved in the effects of
this fiber on the weight management. The above-mentioned
results may suggest that SCF could be used to control obe-
sity, which is considered as a major risk factor for type 2
diabetes.28
The high total cholesterol levels observed in the animals
fed SCF seem be an apparent consequence of the increased
levels of HDL cholesterol. Nowadays, the beneficial ef-
fects of elevated HDL cholesterol levels are evident. It is
worth noting that a highly significant decrease in triglyc-
eride levels during the study was observed in the rats fed
the SCF-enriched diet. The improvement of the lipid pro-
file observed in this study when SCF was administered is in
agreement with the results of other studies carried out with
different fibers in rats10,29–31 and in humans.32 The pres-
ence of cocoa polyphenols in SCF could also explain
the good results obtained in this group in the lipid profile.
The total polyphenols and antioxidant capacity of SCF
have been previously reported.10 The values are
23.9 0.11 mg=g and 569 76 mmol of Trolox equiva-
lents=g of dry matter for total polyphenols and oxygen
radical absorbance capacity, respectively. In addition, the
analysis of profile of flavan-3-ols showed an important
amount of monomers of low molecular weight related to
the functional properties of cocoa polyphenols. The
reported values for catechin, epicatechin, and pro-
cyanidins B1 and B2 were 0.088 0.002, 0.100 0.003,
0.093 0.002, and 0.039 0.007 mg=g of dry matter,
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respectively.10 In fact, increased HDL cholesterol and
decreased triglyceride levels have been reported after the
intake of dark chocolate or cocoa extracts rich in cocoa
polyphenols.33
The present results demonstrate that the Zucker fatty rats
digest fat much better than the Zucker lean rats. The obese
animals eliminate much less fat in their feces than their lean
counterparts. Therefore, the observed increase in FAD in
Zucker fatty rats could be a mechanism involved in the
obese condition of this strain. The decrease in FAD obser-
ved in the SCF-fed group suggests a decrease of cholesterol
intestinal absorption. This could be another mechanism in-
volved in the hypocholesterolemic effect of SCF observed
in this study. The possible mechanisms involved in the hy-
pocholesterolemic effect of dietary fiber are controversial,
but the low fat absorption as a possible mechanism of action
to justify the improvement of the lipid profile has been pre-
viously reported in animals34 and humans.35,36
In this study we have also observed a significant decrease
in plasma glucose and in insulin levels in the Zucker fatty
rats fed the SCF-enriched diets. In fact, the values of fasting
blood glucose in the SCF-fed group during the last weeks of
the study were quite similar to the values of the lean group.
The reduction in insulin concentrations in the rats fed the
fiber-enriched diet is in accordance with results previ-
ously described by other authors.31,37,38 Actually, fiber con-
sumption remained significantly associated with fasting
insulin.25 A link of low insulin concentrations and the re-
duction in body weight gain has been previously de-
scribed,24,25,27 and this connection could even explain the
decrease of body weight observed in the rats fed the fiber-
enriched diet. According to the low fasting glucose and in-
sulin values obtained, the HOMA-IR was reduced in the
group fed the fiber-enriched diet. These results are in
agreement with other authors who reported that the intake of
dietary fiber was inversely associated with HOMA-IR.21,39
The improvement of glucose homeostasis noted in our study
in the fiber-fed group could be associated with the low
glucose uptake induced by SCF. As a consequence of the
low blood glucose levels, the pancreatic secretor capacity
would be reduced, producing a lesser amount of insulin.
This hypothesis would be confirmed by the assessed low
HOMA-b and insulin values obtained in the SCF-fed group.
Therefore, SCF exhibited a beneficial effect on glucose
homeostasis when it was consumed by Zucker fatty rats, and
this effect was likely due to the blood glucose reduction
produced by this fiber in these animals.
It is well established that blood pressure in Zucker fatty
rats is lower between 8 and 12 weeks of life than in their lean
counterparts, and this fact was also corroborated in our
study. However, it has been described that from week 24 of
life this phenomenon is inverted, and the Zucker fatty rats
show elevated blood pressure levels compared with the
lean animals.19 Therefore, the Zucker fatty rats could be
considered as prehypertensive animals.40,41 Even if the
animals used in this study were not a typical hypertensive rat
model, we observed a slight decrease in blood pressure from
3–4 weeks in the rats fed SCF. It has been described that
fiber intake could be implicated in the control of hyperten-
sion,30,42 and significant changes in SBP and DBP have been
reported with fiber supplementation in hypertensive and
older humans.43 In some studies, however, 8 weeks of fiber
intake was required to obtain a blood pressure-lowering
effect.44 The loss of weight and the improvement of insulin
resistance are frequently associated with a decrease in blood
pressure.45–47 The decrease in food intake, body weight, and
insulin resistance produced by SCF could be related with the
blood pressure-lowering effect observed. In addition, this
effect could be also due to the presence of small quantities of
polyphenols in SCF.10 In fact, an amount of these antioxi-
dant compounds as small as 30 mg=day has been demon-
strated to reduce arterial blood pressure in humans.48 To
corroborate the potential antihypertensive effect of SCF, we
are currently conducting some studies in spontaneously
hypertensive rats, which constitute an accepted experimen-
tal model for human essential hypertension. The long-term
intake of SCF clearly attenuates the development of hy-
pertension in these animals (authors’ unpublished data).
Overall, the results obtained point out that SCF may
modulate parameters that appear altered in the metabolic
syndrome such as body weight, glycemia, insulinemia,
lipids, and blood pressure. It seems possible that dietary
percentages of SCF lower than that used in the present
study will also exhibit beneficial health effects in pre-
venting risk factors associated with cardiometabolic dis-
orders. The development of a new source of natural fiber
from a waste product from the chocolate industry as cocoa
husk could also offer a valuable and cheap source of die-
tary fiber and would allow more flexible applications in the
food industry. In addition, the difference in the chemical
structure of SCF and other fibers, responsible for their
physical properties, and also the presence of cocoa poly-
phenols may explain the good results obtained with SCF.
All this could justify the use of this fiber from this source
relative to other sources. Additional studies with SCF are
necessary to completely elucidate the mechanism(s) in-
volved in the modulation of the parameters studied. In any
case, in order to incorporate SCF as a functional food in-
gredient for obese patients and=or patients with the meta-
bolic syndrome, its efficiency and safety in these patients
should be determined.
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